Resveratrol: A Multifunctional Cytoprotective Molecule

Juhász, Béla; Varga, Balázs; Gesztelyi, Rudolf; Kemény-Beke, Ádám; Zsuga, Judit; Tósaki, Árpád

doi:10.2174/138920110793262079

Cited by 52 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, numerous previous studies have revealed that resveratrol affects many cell biological responses such as insulin sensitivity, gluco/lipotoxicity, endoplasmic reticulum stress, oxidative stress etc., all of which contribute to diabetes, in particular type 2 diabetes [46]. Our findings here define one of the immune suppressive functions of resveratrol in protecting mice from diabetes.…”

Section: Discussionsupporting

confidence: 56%

Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

et al. 2011

View full text Add to dashboard Cite

Aims/hypothesis We recently found that activation of the type III histone deacetylase sirtuin 1 suppresses T cell immune responses. Here we sought to determine the therapeutic potential of the sirtuin 1 activator resveratrol in the treatment of diabetes in the NOD mouse model of type 1 diabetes and the mechanisms underlying such potential. Methods NOD mice were fed or subcutaneously injected with resveratrol and evaluated for development of diabetes. Splenocytes from resveratrol-treated and control mice were analysed by gene array. The altered expression of inflammatory genes induced by resveratrol was validated and the role of changed gene expression in prevention of diabetes was determined. Results Resveratrol administration potently prevented and treated type 1 diabetes in NOD mice. Gene array analysis indicated a dramatic decrease in expression of Ccr6, which encodes chemokine (C-C motif) receptor (CCR) 6, in the splenocytes from resveratrol-treated mice. CCR6 abundance on IL-17-producing cells and CD11b+F4/80hi macrophages was inhibited by resveratrol treatment. Interestingly, CCR6+ IL-17-producing cells and CD11b+F4/80hi macrophages accumulated in the spleens and pancreatic lymph nodes, but their presence in the pancreas was reduced, suggesting that resveratrol blocks their migration from peripheral lymphoid organs to the pancreas. Indeed, the migration of splenocytes toward media containing chemokine (C-C motif) ligand 20 (CCL20) was impaired by resveratrol treatment. CCL20 peptides, which block CCR6 binding to CCL20, inhibited development of type 1 diabetes. Conclusions/interpretation Inhibition of CCR6-mediated migration of inflammatory cells by resveratrol may provide a powerful approach for treatment of type 1 diabetes and possibly of other inflammatory diseases.

show abstract

Section: Discussionsupporting

confidence: 56%

Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Understanding OSIPS in WJ-MSC is a prelude to developing protective measures against stress-induced premature senescence. Resveratrol is one of more successful drugs shown to exert such protective effects under various laboratory conditions in cell and animal models 46-48. It remains to be investigated if resveratrol exert similar desirable effects on WJ-MSC.…”

Section: Discussionmentioning

confidence: 99%

Oxidative Stress-Induced Premature Senescence in Wharton's Jelly-Derived Mesenchymal Stem Cells

Choo¹,

Tai²,

Hymavathee³

et al. 2014

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: On in vitro expansion for therapeutic purposes, the regenerative potentials of mesenchymal stem cells (MSCs) decline and rapidly enter pre-mature senescence probably involving oxidative stress. To develop strategies to prevent or slow down the decline of regenerative potentials in MSC culture, it is important to first address damages caused by oxidative stress-induced premature senescence (OSIPS). However, most existing OSIPS study models involve either long-term culture to achieve growth arrest or immediate growth arrest post oxidative agent treatment and are unsuitable for post-induction studies. Methods: In this work, we aimed to establish an OSIPS model of MSCs derived from Wharton's Jelly by hydrogen peroxide (H2O2) treatment. Results: The optimal H2O2 concentration was determined to be 200 µM to achieve OSIPS when MSC reached growth arrest in 3 to 4 passages post-H2O2 treatment. H2O2-treated cells became heterogeneous in morphology, and were irregularly enlarged and flattened with granular cytoplasm. The cells were stained positive for SA-β-galactosidase, a senescence marker, and were shown to express elevated levels of other well-characterized senescence molecular markers, including p53, p21, p16 and lysosomal β-galactosidase (GLB1) in real-time RT-PCR analysis. The OSIPS-like features were confirmed with three independent WJ-MSC lines. Conclusion: The establishment of an OSIPS model of WJ-MSC is a first step for subsequent investigation on molecular mechanisms of senescence and for screening potential anti-oxidative agents to delay or revert stressed-induced senescence.

show abstract

“…In the past decade, resveratrol, a naturally occurring polyphenolic compound, found predominantly in grapes and peanuts, has been widely documented in the scientific literature for its beneficial effects in preventing and/or managing several diseases [13, 14]. Over the past 6 years, we have reported potent effects of resveratrol in preventing or reversing cardiac impairment in animal models of hypertension and obesity [5, 15, 16].…”

Section: Introductionmentioning

confidence: 99%

Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Movahed

Nabipour

Louis

et al. 2013

Evidence-Based Complementary and Alternative Medicine

213

182

View full text Add to dashboard Cite

The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial. A total of 66 subjects with type 2 diabetes were enrolled in this study and randomly assigned to intervention group which was supplemented with resveratrol at a dose 1 g/day for 45 days and control group which received placebo tablets. Body weight, blood pressure, fasting blood glucose, haemoglobin A1c, insulin, homeostatic assessments for insulin resistance, triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, and markers of liver and kidney damage were measured at baseline and after 45 days of resveratrol or placebo supplementation. Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels. On the other hand, the placebo group had slightly increased fasting glucose and LDL when compared to their baseline levels. Liver and kidney function markers were unchanged in the intervention group. Overall, this study showed that resveratrol supplementation exerted strong antidiabetic effects in patients with type 2 diabetes.

show abstract

Resveratrol: A Multifunctional Cytoprotective Molecule

Cited by 52 publications

References 0 publications

Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes

Oxidative Stress-Induced Premature Senescence in Wharton's Jelly-Derived Mesenchymal Stem Cells

Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

Contact Info

Product

Resources

About